The nurse is caring for a client with neurogenic diabetes insipidus and administers what drug to treat the condition.

Glulisine is a rapid-acting insulin that has an onset of action of 2 to 5 minutes and peaks in 30 to 90 minutes, making it the fastest among the choices. Some possible explanations for the other choices are:

Choice A. Aspart is also a rapid-acting insulin, but it has a slightly longer onset of action (10 to 20 minutes) and peak time (1 to 3 hours) than glulisine.

Choice B. Lispro is another rapid-acting insulin, but it has a similar onset of action (<15 minutes) and peak time (30 to 90 minutes) as glulisine, so it is not the fastest.

Choice C. Regular is a short-acting insulin that has a much longer onset of action (30 to 60 minutes) and peak time (2 to 4 hours) than glulisine, so it is not suitable for fast therapeutic effects.

Normal ranges for blood glucose levels are 70 to 130 mg/dL before meals and less than 180 mg/dL after meals.

Insulin doses are adjusted based on blood glucose monitoring, carbohydrate intake, physical activity, and other factors.

Tolbutamide is preferred for clients with renal dysfunction, who may not be able to excrete chlorpropamide, because it is more easily cleared from the body.

Choice B. Tolazamide is wrong because it is a first-generation sulfonylurea that is used less frequently and is usually tried after tolbutamide and chlorpropamide have been shown to be ineffective.

Choice C. Chlorpropamide is wrong because it is a first-generation sulfonylurea that may accumulate in clients with renal dysfunction and cause hypoglycemia.

Choice D. Chlorpromazine is wrong because it is an antipsychotic agent, not an oral antidiabetic agent.

First-generation sulfonylureas are oral antidiabetic agents that stimulate insulin secretion from the pancreas.

They are used to treat type 2 diabetes mellitus.

The normal range of blood glucose level is 70 to 110 mg/dL.